Differences in the clinical characteristics and the cellular composition of the high and low IFNG AD subgroups warrant future research on additional immune pathways, such as type 1-related pathways, involved in AD pathogenesis aside from type 2 immunity. This evidence concerns the gene IFNG and Alzheimer disease.